NASD · Healthcare · Biotechnology · France
DBV Technologies ADR is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
DBV Technologies is a specialty biopharmaceutical company developing Viaskin, a patch-based technology for delivering immunotherapy through intact skin. The company is advancing Viaskin Peanut Patch to treat children with peanut allergy, with additional programs for milk allergy and other conditions. The approach targets immune cells in the skin to induce tolerance without systemic exposure.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the DBV Technologies ADR stock.
Not valued: We cannot value this company yet.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on DBVT yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.